Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6180)	10/31/1998 7:52:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

erectile dysfunction; viagra offers hope, but germans to pay for potency October 28, 1998 Impotence & Male Health Weekly Plus via NewsEdge Corporation : Millions of German men could find their sex lives revitalized after Viagra makes its debut across the country, but it is to be had at a price. Viagra, produced by U.S. drugs company Pfizer, costs between 18 and 26 marks ($11 and $16) a tablet and the company's German branch said it expected sales of around one billion marks for the year. Hartmut Porst, a Hamburg urologist, said there were some four million men in Germany, a country of 80 million, suffering from serious impotence problems. The Federal Committee of Doctors and Health Funds ruled in August 1998 that for financial reasons patients would have to pay for Viagra themselves. As in France, Italy and Denmark, the German government agreed the drug - approved for use in the European Union in September 1998 - should not be available on prescription, except when a patient was known to be suffering from a specific illness. Porst said it was incomprehensible not to classify impotency as an illness. Many of his patients had said they intended to complain about the ruling forcing them to pay for treatment, he added. But private medical plans in Germany have said they are considering reimbursing their members in cases of medical necessity. In the United States where the drug was first launched around 35 million tablets had been sold since April, said head of Pfizer's German unit Werner Soukup.